Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

NCT02212886 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: GA Depot 80 mg
DRUG: GA Depot 40 mg

Sponsor

Mapi Pharma Ltd.